logo-loader

Open Orphan on US$13.4m contract for influenza human challenge study, their third flu deal this year

Published: 08:34 13 Dec 2021 GMT

Open Orphan PLC (AIM:ORPH, OTC:OPORF)'s (Open Orphan PLC (AIM:ORPH, OTC:OPORF)) Cathal Friel tells Proactive, Hvivo, a subsidiary has signed a $13.4m (€11.8m) contract with a US-based biotechnology company.

The deal is to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model.The study is expected to start in the second half of 2022 and will be conducted at hVIVO's state-of-the-art quarantine facilities in London, the company said in a statement.

It expects most of the revenues from the contract to be recognised in 2022.

hVIVO chairman Cathal Friel says he remains committed to hVIVO following...

hVIVO PLC (AIM:HVO) chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions while...

on 19/2/24